Study Overview: This study is testing RGX-314, a one-time gene therapy, for people with wet AMD, a condition causing vision loss from leaky blood vessels in the eye. Current treatments require frequent eye injections. RGX-314 may offer a longer-lasting solution.

Details: 115 participants will be in this study, divided into 6 groups called cohorts. Some will receive the RGX-314 therapy and others will get a standard treatment named ranibizumab. Each group will get different doses of RGX-314 to check its safety and effectiveness.

Eligibility: To join, participants must be 50-89 years old, have a specific type of eye condition called CNV, and have responded well to current anti-VEGF treatments. They must provide written consent. People with certain eye surgeries or other conditions in the last 6 months cannot participate.

• **Study Length:** Varies by cohort; involves multiple visits.
• **Risks and Benefits:** RGX-314 aims to reduce frequent injections but has different doses and potential risks.
• **Compensation:** Not specified; participants should inquire during enrollment.